Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefepime/nacubactam or aztreonam/nacubactam vs imipenem/cilastatin in complicated UTI/acute pyelonephritis
NCT05887908Phase 3Completed
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- May 2023
- Primary completion
- Nov 2024
- Modality
- Multivalent & Scaffold-Based Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of Nacubactam in complicated urinary tract infection (cUTI), acute pyelonephritis, sponsored by Meiji Seika Pharma Co., Ltd.. Started May 2023; status: completed.
02
Drugs
Nacubactam
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on NCT05887908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05887908.